Published in Cardiovascular Business Week, February 1st, 2005
The updated product label is in follow-up to the letter issued to healthcare providers in August 2004, regarding an increased risk of arterial thromboembolic events (ATEs) associated with the use of Avastin in combination with chemotherapy.
An analysis of 1745 patients treated in Avastin clinical trials showed that ATEs occurred...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.